Actuality of study the vascular endothelial growth factor in patients with arteriovenous malformation

Keywords: arteriovenous malformation; neoangiogenesis; endothelial vascular growth factor; VEGF.

Abstract

Objective – to determine the role of endothelial vascular growth factor (VEGF) in the formation, progression of arteriovenous malformations (AVM), the occurrence of relapses of this disease and to justify the need to study the level of VEGF in blood plasma in patients with AVM.
Materials and methods. The analysis of 15 sources of scientific and medical literature on the etio-logy and pathogenesis of AVM. Recent data of studies of the role of VEGF in the formation, progression of AVM, occurrence of relapses of this disease have been systematized. The own results of the study of the level of VEGF in blood plasma in 19 patients with AVM of different localization are presented.
Results. The important role of increasing the level of VEGF in the formation, progression of AVM, both according to scientific and medical literature and according to own research, has been proved. The necessity to study the level of VEGF in blood plasma in patients with AVM in the perioperative period to improve the effectiveness of complex treatment of such patients is substantiated.
Conclusions. Endothelial vascular growth factor plays an important role in the formation, progression of arteriovenous malformations. Increased level of VEGF in blood plasma in patients with AVM was noted. Increased levels of VEGF in blood plasma after surgical or endovascular treatment may cause relapses of the disease. Changes in the level of VEGF in blood plasma after surgical or endovascular treatment have not been studied at present. Studying the level of VEGF in blood plasma before and after surgical and endovascular treatment opens new possibilities for the use of drugs that block the action of VEGF as a neoadjuvant therapy for the prevention of recurrence or regression of stroke.

Downloads

Download data is not yet available.

References

Lee BB, Baumgartner I, Berlien HP et al. Consensus Document of the International Union of Angiology (IUA)-2013. Current concept on the management of arterio-venous management. Int Angiol. 2013;32:9-36. PMID: 23435389

Orlov MJu, Orlov JuA, Jarockij JuJa. Ostrye narushenija mozgovogo krovoobrashhenija kak manifestacija arteriovenoznyh malformacij golovnogo mozga u detej. Zb. nauk. prac spіvrobіt. NMAPO іm. P.L. Shupika. 2013;22(1):177-81. (in Russian)

Ernemann U, Kramer U, Miller S et al. Current concepts in the classification, diagnosis and treatment of vascular anomalies. Eur J Radiol. 2010;75(1):2-11. doi: 10.1016/j.ejrad.2010.04.009.

Shheglov DV, Barkanov AV, Svyrydjuk OJe ta in. Arteriovenozni malformacii golovnogo mozku. Suchasni pogljady na problemu Zb. nauk. prac spivrobit. NMAPO im. P.L. Shupyka. 2013;22(1):264-71. (in Ukrainian)

Cho SK, Do YS, Shin SW. Arteriovenous malformation of the body and extremities: analysis of theraputic outcomes and approaches according to modified angiographic classification. J Endovasc Ther. 2006;13:527-38. PMID: 16928170. DOI: 10.1583/05-1769.1

Poceluev DD, Musagaliev DT, Kospanov NA i dr. Rezultaty jendovaskuljarnyh hirurgicheskih vmeshatelstv pri arteriovenoznyh malformacijah konechnostej. Innovacionnye tehnologii v hirurgii. 2010. https://articlekz.com/article/6529. (in Russian)

Leblanc GG, Golanov E, Awad IA, Young WL. Bio-logy of vascular malformations of the brain. Stroke. 2009;40(12):e694-e702. doi: 10.1161/STROKEAHA. 109.563692.

Mizhnarodna statystychna klasyfikacija hvorob ta sporidnenyh problem ohorony zdorovja. Desjatyj peregljad. K.: Zdorovja; 2001. Vol. 3. 817 с. (in Ukrainian)

Mullan S, Mojtahedi S, Johnson DL, Macdonald RL. Embryological basis of some aspects of cerebral vascular fistulas and malformations. J Neurosurg. 1996;85(1):1-8. PMID: 8683257. DOI:10.3171/jns.1996.85.1.0001

Han C, Choe SW, Kim YH et al. VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2. Angiogenesis. 2014 Oct;17(4):823-30. doi: 10.1007/s10456-014-9436-3.

Boon LM. Pathogenesis of vascular anomalies. Clin Plast Surg. 2011;38:7-19. doi: 10.1016/j.cps.2010.08.012.

Walker EJ, Su H., Shen F et al. Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain. Stroke. 2012;43(7):1925-30. doi: 10.1161/STROKEAHA.111.647982.

Bevacizumab treatment for brain arteriovenous malformations. 2014. https://clinicaltrials.gov/ct2/show/NCT02314377.

Sandalcioglu IE, Wende D, Eggert A et al. Vascular endothelial growth factor plasma levels are significantly elevated in patients with cerebral arteriovenous malformations. Cerebrovasc. Dis.2006; 21(3):154-58. doi: 10.1159/000090526.

Kochanowski J, Sobieszczanska M, Tubek S et al. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia. Hum Vaccin Immunother. 2015;11(3):680-1. doi: 10.1080/21645515.2015.1011960.


Abstract views: 48
PDF Downloads: 22
Published
2020-03-11
How to Cite
Altman, I. (2020). Actuality of study the vascular endothelial growth factor in patients with arteriovenous malformation. Endovascular Neuroradiology, 30(4), 59-67. https://doi.org/10.26683/2304-9359-2019-4(30)-59-67